Top in endocrinology: Benefits of morning exercise; COVID-19 booster alters glucose levels
By performing physical activities in the mornings or afternoons, adults may lower their risk for developing type 2 diabetes. The same could not be said for those who exercise during the evening.
It was the top story in endocrinology last week.

Another top story was about how adults who receive the COVID-19 booster may have elevated glucose levels for a few days after.
Read these and more top stories in endocrinology below:
Exercise in morning or afternoon better than evening for lowering type 2 diabetes risk
Physical activity during the morning and afternoon, but not during the evening, is associated with a lower risk for developing type 2 diabetes, according to findings published in Diabetologia. Read more.
COVID-19 booster may cause small increase in glucose for some with type 1 diabetes
Adults with type 1 diabetes may have transient increases in glucose levels in the days after receiving a COVID-19 vaccine booster, according to a study published in Diabetes Research and Clinical Practice. Read more.
Most adults, children with type 1 diabetes report benefits with use of bionic pancreas
Most people with type 1 diabetes using an insulin-only bionic pancreas said the device provided more benefits than burdens and stated they would recommend the device, according to findings published in Diabetes Technology & Therapeutics. Read more.
Providers concerned about safety, liability with providing transgender care for youths
State legislation prohibiting gender-confirming medical care for children and adolescents may lead to decreased access as pediatric endocrinology providers expressed concerns about their ability to practice in a survey. Read more.
‘Watershed moment’: Obesity care in the spotlight as more drugs become available
With reports of dramatic weight loss achieved using a new generation of diabetes drugs — one FDA approved for weight loss and another with a decision expected this fall — more adults are seeking medical therapy for obesity. Read more.